Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

As more biomarker-based tests become prevalent, options for identifying and treatment prostate cancer are going to expand. Prostate-specific antigen (PSA) screenings aren’t going away, says Carroll, but other types of testing should become standard in the future to reduce the amount of unnecessary biopsies.

Once a PSA has identified a high-risk patient, follow-up serum tests or imaging tests should be conduced to determine which patients will benefit from a biopsy.